About us

The UCL Institute of Immunity and Transplantation (IIT) is an international centre of excellence in immunology research. It is a hub for experimental medicine, transferring novel research concepts into new diagnostic tools and therapeutic interventions for the local and global patient population.

Multidisciplinary research and training programs serve to educate scientists and health professionals. Joint working accelerates the implementation of novel immunotherapies as routine treatment.

The IIT aims to develop vaccinations, gene therapy and cell therapy to enhance immunity in patients with cancer and chronic infection, and to induce tolerance in autoimmune diseases and in patients receiving conventional or bioengineered transplants. 

The research activities of the IIT are grouped in three research clusters, with each cluster containing two related programs of research::

Cluster Program
Immune tolerance
  • Immune regulation
  • Bioengineered tissue transplantation
  • Immunotherapy of cancer
  • Viral immunity
Inherited disease
  • Gene therapy of inherited defects
  • Immunodeficiency

The IIT is part of the UCL Division of Infection and Immunity. It is an  important component of the research strategy of the Academic Health  Science Centre of UCL-Partners. The IIT is developed in partnership  between UCL, Royal Free London NHS Foundation Trust and the Royal  Free Charity and is delivered in two phases: i) Phase I is a £6 million  investment providing newly refurbished space and was opened in June  2013; ii) Phase II will provide a new state of the art research building  which is due to open in 2017. A grant award from the UK-Research  Partnership Investment Fund provides £33 million funding to support  the construction the new research building.

Page last modified on 26 mar 15 14:45